Related Experiment Video
Updated: Dec 8, 2025

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study
Published on: April 18, 2025
Integrative oncology from a bibliometric point of view
1Department of Sociology, Umeå University, 901 87 Umeå, Sweden.
Objectives:
The aim of this article is to analyze the development of integrative oncology from a bibliometric point of view. The publication and citation patterns of publications are analyzed and their contents mapped.
Design:
This study is based on bibliometric methods. The data sets consist of 7 025 respectively 4 990 publications over the time period 1966-2016, shown in PubMed and Web of Science.
Results:
The expansion of the numbers of these publications took place in the late 1990s/early 2000s. Research is dominated by authors located in the USA, China and Germany who are working at well-established research universities and university hospitals. The clinical share of publications is relatively small, and few studies are classified according to clinical phase. Content analysis revealed that much of the clinical research is based on surveys, and that content reflects the intersection of complementary therapies and cancer research. The latter aspect is less obvious in pre-clinical research. The most frequent journals in the material show a focus on complementary and alternative therapies or on integrative oncology, although journals focused on oncology or general/internal medicine were well-represented in the material as a whole. The most-cited publications were review articles and surveys.
Conclusions:
Integrative oncology has been established as a small, but distinct, research domain. There are several signs of specialization in integrative oncology, but also in its integration into general medical and oncological research.
More Related Videos
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Genomics
Tumor Immunotherapy
Activation of Integrins
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...

